- The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis2022 | 1. lékařská fakulta
- Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution2019 | 1. lékařská fakulta
- Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries2023 | 1. lékařská fakulta
- Real-world Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients with Psoriatic Arthritis in Thirteen European Countries2022 | 1. lékařská fakulta
- Treatment response and drug retention rates in 24 195 biologic-naive patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration2019 | 1. lékařská fakulta
- Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching2023 | 1. lékařská fakulta
- Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration2022 | 1. lékařská fakulta
- Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration2018 | 1. lékařská fakulta
- Self-perceived general health at start of TNFi therapy predicts therapeutic response in patients with rheumatoid arthritis: analysis from the ATTRA registry2022 | Ústřední knihovna, 1. lékařská fakulta
- Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration2008 | Ústřední knihovna, 1. lékařská fakulta
- The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry2022 | 1. lékařská fakulta
- Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis2016 | 1. lékařská fakulta